Atopic Dermatitis/Skin Diseases

Top Story

Novel hereditary angioedema therapy reduces attacks, treatment-related costs

Novel hereditary angioedema therapy reduces attacks, treatment-related costs
November 10, 2017

BOSTON — A C1-esterase inhibitor (human) delivered subcutaneously for the treatment of long-term prophylaxis associated with hereditary angioedema decreased attacks by 90% compared with therapy administered intravenously, according to findings presented at the ACAAI Annual Scientific Meeting.

Additionally, the researchers determined that total attack-related drug and other medical costs were reduced by 89% over the span of 1 year in a patient treated with C1-esterase inhibitor subcutaneous (human) (Haegarda, CSL Behring) compared with intravenous treatment.

Meeting NewsVideo

VIDEO: New treatment developments on the horizon for acute hereditary angioedema

October 28, 2017
BOSTON — The landscape of hereditary angioedema and how it is diagnosed, assessed and treated has been ever-evolving and will continue to change as new treatment…
Meeting News

Pediatric eczema linked to severe asthma-related hospitalization

October 27, 2017
BOSTON — Although total immunoglobulin E levels were unrelated to severity of hospital stay, children experience increasingly intense hospital courses if they have…

ACAAI annual meeting to showcase new discoveries, treatments

October 6, 2017
Healio.com/Allergy will present live coverage of the 75th American Academy of Allergy, Asthma and Immunology annual meeting from Boston beginning Oct. 26 through Oct…
More Headlines »